Where are we in the search for noninvasive nonalcoholic steatohepatitis biomarkers?

Hepatology

Volumn 54, Issue 4, 2011, Pages 1115-1117

  Mato, José M ^a   Lu, Shelly C ^b  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ALKALINE PHOSPHATASE; ALPHA 2 MACROGLOBULIN; APOLIPOPROTEIN A1; BILIRUBIN; BIOLOGICAL MARKER; CHOLESTEROL; COLLAGEN; COLLAGENASE; FERRITIN; GAMMA GLUTAMYLTRANSFERASE; GLUCOSE; GLYCOPROTEIN; HAPTOGLOBIN; PLATELET DERIVED GROWTH FACTOR; POLYSACCHARIDE; TRANSFORMING GROWTH FACTOR BETA1; TRIACYLGLYCEROL;

ALKALINE PHOSPHATASE BLOOD LEVEL; BODY MASS; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC IMAGING; DIAGNOSTIC TEST; DISEASE MARKER; ECHOGRAPHY; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HUMAN; INTERMETHOD COMPARISON; LIVER BIOPSY; LIVER FIBROSIS; METABOLOMICS; NONALCOHOLIC FATTY LIVER; NONHUMAN; NOTE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; SENSITIVITY AND SPECIFICITY; THROMBOCYTE COUNT; TRANSIENT ELASTOGRAPHY; WAIST CIRCUMFERENCE;

ADULT; AGE DISTRIBUTION; BIOLOGICAL MARKERS; BIOPSY, NEEDLE; CHILD; EARLY DIAGNOSIS; FATTY LIVER; FEMALE; HEPATITIS; HUMANS; INCIDENCE; INSULIN RESISTANCE; MALE; NEEDS ASSESSMENT; OBESITY; PROGNOSIS; RISK FACTORS; SPAIN;

EID: 80053334870     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.24642     Document Type: Note

References (13)

1. Bedogni G, Miglioli L, Masutti F, Tiribelli C, Marchesini G, Bellentani S. Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. HEPATOLOGY 2005; 42: 44-52.
2. Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. HEPATOLOGY 2004; 40: 1387-1395.
3. Calori G, Lattuada G, Ragogna F, Garancini MP, Crosignani P, Villa M, et al. Fatty liver index and mortality: The cremona study in the 15th year of follow-up. HEPATOLOGY 2011; 54: 145-152.
4. Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. HEPATOLOGY 2010; 51: 1820-1832.
5. Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. HEPATOLOGY 2003; 37: 1202-1219.
6. Rockey DC, Caldwell SH, Goodman ZD, Nelson RC, Smith AD; for American Association for the Study of Liver Diseases. Liver biopsy. HEPATOLOGY 2009; 49: 1017-1044.
7. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Nonalcoholic Steatohepatitis Clinical Research Network. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. HEPATOLOGY 2005; 41: 1313-1321.
8. Hernaez R, Lazo M, Bonekamp S, Kamel I, Brancati FL, Guallar E, et al. Diagnostic accuracy and rellability of ultrasonography for the detection of fatty liver: a meta-analysis. HEPATOLOGY 2011; doi:10.1002/hep.24452.
9. Rockey DC, Bissell DM. Noninvasive measures of liver fibrosis. HEPATOLOGY 2006; 43: S113-S120.
10. Nguyen D, Talwalkar JA. Noninvasive assessment of liver fibrosis. HEPATOLOGY 2011; 53: 2107-2110.
11. Poynard T, Ratziu V, Charlotte F, Messous D, Munteanu M, Imbert-Bismut F, et al. Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol 2006; 6: 34.
12. Barr J, Vázquez-Chantada M, Alonso C, Pérez-Cormenzana M, Mayo R, Galán A, et al. Liquid chromatography-mass spectrometry-based parallel metabolic profiling of human and mouse model serum reveals putative biomarkers associated with the progression of nonalcoholic fatty liver disease. J Proteome Res 2010; 9: 4501-4512.
13. Puri P, Wiest MM, Cheung O, Mirshahi F, Sargeant C, Min HK, et al. The plasma lipidomic signature of nonalcoholic steatohepatitis. HEPATOLOGY 2009; 50: 1827-1838.